Skip to main content
SpringerLink
Log in

ICER’s Revised Value Assessment Framework for 2017–2019: A Critique

  • Commentary
  • Published:
PharmacoEconomics Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Institute for Clinical and Economic Review. Overview of the ICER assessment framework and update for 2017–2019. https://icer-review.org/wp-content/uploads/2017/06/ICER-value-assessment-framework-update-FINAL-062217.pdf. Accessed 24 Jul 2017.

  2. Neumann PJ, Sanders GD, Russell LB, Siegel JE, Ganiats TG, editors. Cost-effectiveness in health and medicine. 2nd ed. New York: Oxford University Press; 2016.

    Google Scholar 

  3. Lakdawalla D, Neumann PJ. Budget criteria and drug value assessments: a case of apples and oranges? Health Affairs Blog. 22 Sep 2015. http://healthaffairs.org/blog/2016/09/22/budget-criteria-and-drug-value-assessments-a-case-of-apples-and-oranges/. Accessed 24 Jul 2017.

  4. Neumann PJ, Cohen JT. Measuring the value of prescription drugs. N Engl J Med. 2015;373:2595–7.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, #063, 800 Washington St., Boston, MA, 02111, USA

    Peter J. Neumann & Joshua T. Cohen

Authors
  1. Peter J. Neumann
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Joshua T. Cohen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Peter J. Neumann.

Ethics declarations

Funding

No funding was received for this commentary.

Conflicts of interest

The Center for the Evaluation of Value and Risk in Health at Tufts Medical Center receives funding from numerous government, non-profit foundation, and pharmaceutical industry sources. Both Drs Neumann and Cohen have frequently consulted with the pharmaceutical industry and serve as consultants to Precision Health Economics.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Neumann, P.J., Cohen, J.T. ICER’s Revised Value Assessment Framework for 2017–2019: A Critique. PharmacoEconomics 35, 977–980 (2017). https://doi.org/10.1007/s40273-017-0560-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40273-017-0560-y

Search

Navigation